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Available online 15 December 2015Factor X (FX) deﬁciency is an autosomal recessive severe bleeding disorder. Here, we identiﬁed a novel homozy-
gousmissensemutation (p.Ala275Val) in the F10 gene in a patient with severe FX deﬁciency. The novelmutation
was analyzed by in vitro expression and modeling. Site-directed mutagenesis of FX cDNA was used to introduce
the FX Ala275Val mutation, wild-type as well asmutant FX proteins were expressed in HEK293 cells, and subcel-
lular localization experiments were performed. Expression experiments showed that the FX Ala275Val mutation
led to a signiﬁcant reduction in antigen and activity levels in the culture medium. Moreover, compared to the
wild-type, mutant FX-Ala275Val was mainly distributed in the endoplasmic reticulum and rarely entered the
Golgi apparatus, suggesting a transportation defect for FX from the endoplasmic reticulum to theGolgi apparatus.
Molecular modeling analysis indicated that the Ala275 is spatially located to the catalytic triad of FXa, which is
composed of His276, Asp322, and Ser419. The Ala to Val substitution may change the conformation of the cata-
lytic pocket and alter protein folding and enzymatic activity. Our ﬁndings demonstrated that the Ala275Val sub-
stitution is a pathogenic mutation that causes the inherited FX deﬁciency.







Human coagulation factor X (FX) is a vitamin K-dependent plasma
serine protease that plays a key role in the coagulation cascade, acting
as the ﬁrst enzyme in the common pathway of thrombin generation
[1]. Following activation to FXa, the protease is complexedwith activat-
ed factor V, a negatively charged membrane surface, and Ca2+ to form
the prothrombin complex, which then cleaves prothrombin and subse-
quently generates thrombin. FX can be physiologically activated by
either the tissue-factor/FVIIa complex in the extrinsic pathway or the
FIXa/FVIIIa complex in the intrinsic pathway. It is also activated
in vitro by a speciﬁc enzyme isolated from Russell's viper venom [2].
FX is synthesized in the liver as a precursor with a 40-residue
prepropeptide that targets the protein for secretion [3] and is proteolyt-
ically cleaved before secretion. The mature FX is then secreted into the
plasma as a two-chain protein consisting of a 17-kDa light chain and a
45-kDa heavy chain that are linked together by a disulﬁde bond [4].
The protein structure of FX consists of a Gla domain, two epidermal
growth factor (EGF)-like domains, an activation peptide, and a catalytic
serine protease domain; it is structurally homologous to other vitamintology, Institute of Molecular
l South University, No. 139
. This is an open access article underK-dependent proteins such as prothrombin (FII), FVII, FIX, protein C,
and protein S [5]. In the serine protease domain of FX, residues
His276, Asp322, and Ser419 (His57, Asp102, and Ser195 in the chymo-
trypsinogen numbering, respectively) constitute the catalytic site [6].
Inherited FX deﬁciency is a rare and severe autosomal recessive
bleeding disorder. The prevalence of the disease in the general popula-
tion is about 1:1,000,000 and the carrier frequency is about 1:500 [7].
The F10 gene, located on chromosome 13q34 and approximately
2.8 kb downstream of the F7 gene [8], consists of eight exons and
seven introns. Each exon encodes a speciﬁc domain within the protein
[9]. Molecular defects in the F10 gene are the main causative factors
that result in FX deﬁciency. To date, approximately 130 F10 gene muta-
tions have been identiﬁed, including missense, deletions, insertions,
frame shift, and splice site mutations [10], of whichmissensemutations
are predominant. Based on the results of both functional activity and
immunological antigen level, FX deﬁciency can be classiﬁed into two
types: those in which both functional activity and antigen level are
concomitantly decreased are deﬁned as type I, whereas those with
low activity and normal or a near-normal antigen level are deﬁned as
type II [1]. The common clinical manifestations of FX deﬁciency include
easy bruising, hematomas, epistaxis, hemarthrosis, umbilical cord
bleeding, gastrointestinal and central nervous system (CNS) bleeding
[11], which has a poor correlation with laboratory phenotypes [12].
In the present study, we report a novel homozygous Ala275Val mu-
tation in the catalytic domain of the F10 gene in a Chinese patient withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and abnormal subcellular localization of mutated FX protein were
analyzed. The mechanism of bleeding in the patient and molecular
modeling analysis were explored.
2. Materials and methods
2.1. Patient
The proband was a 28-year-old Chinese female born from non-
consanguineous parents. She had experienced repeated gum bleeding,
nose bleeding, and skin ecchymosis after a slight collision during child-
hood. Since hermenarche, the patient has suffered from increasedmen-
strual bleeding and signiﬁcantly longermenstrual period (about 15 days
for everymenstrual period). She had ﬁve pregnancies in total, including
three natural labors and twomiscarriages. Postpartumhemorrhagewas
observed in all pregnancies, and blood transfusion therapy was needed
every time. The mother of the proband had a similar but milder
ecchymosis after collision, and other family members had no history
of bleeding.
2.2. Coagulation assays
The written informed consent was obtained from the patient and
her mother, who participated in the present study. The study was
approved by the Ethics Committee of the Second Xiang-Ya Hospital,
Central SouthUniversity. After receiving their informed consent, venous
blood from the proband and her mother were collected. FX clotting ac-
tivity assay was performed using a one-stage clotting method based on
prothrombin time (PT) or aPTT using FX-deﬁcient plasma on ACL-TOP
700 automatic coagulometer (HemosILTM, IL, MA, USA). FX antigen
level was measured using a commercially available AssayMax Human
Factor X (FX) ELISA Kit (Assay Pro, St. Charles, MO, USA). FX activity
and antigen levels were expressed as the percentage of normal pooled
plasma obtained from 30 healthy individuals, which was set as 100%.
And all of these participants provide their written informed consent to
participate in this study.
2.3. Genetic analysis
Genomic DNA of the proband and her mother were extracted from
peripheral blood leucocytes using a standard protocol (the TIANamp
Genomic DNA Kit, Beijing, China). DNA sequence analysis of the F10
gene was performed as previously described [13], and the mutations
were conﬁrmed by reverse sequencing. To rule out the possibility that
the detected sequence variant of the patient was a common gene poly-
morphism, 110 healthy individuals were screened for this particular
variant as well. Mutationwas named according to the standard interna-
tional nomenclature guidelines recommended by the Human Genome
Variation Society (HGVS at http://www.hgvs.org/mutnomen/recs.
html), with the methionine encoded by the translation initiation site
(start codon) beingnumbered as residue 1. The genomic DNA(GenBank
accession number: 12738260) and cDNA (GenBank accession number:
M57285) sequences of the F10 gene were used as reference sequences.
The sequences of the PCR primers for amplifying all exons and exon/
intron boundaries of the F10 gene are listed in Table S1.
2.4. In silico analysis of amino acid change
The possible impact of the novelmissensemutation on the structure
and function of FX was assessed by using two bioinformatics tools:
Sorting Intolerant from Tolerant (SIFT, http://sift.jcvi.org) and
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/). The protein
ID“P00742”was used. The conservation of the affected amino acids
were further checked by multiple sequence alignment (HomoloGene,
http://www.ncbi.nlm.nih.gov/sites/entrez) with sequences from Pantroglodytes, Macaca mulatta, Canis lupus familiaris, Bos taurus, Mus
musculus, Rattus norvegicus, Gallus gallus, Danio rerio, and Xenopus
tropicalis.
2.5. Construction of expression vectors and site-directed mutagenesis
A 1507-bp gene fragment encompassing the full-length human FX
cDNA was obtained from the entry clone pDONR223-FX (Genechem,
Shanghai, China) by PCR using the forward primer, 5′-ACGGGCCCTCTA
GACTCGAGATGGGGCGCCCACTGCACCTC-3′, and introducing a XhoI
site, and the reverse primer, 5′-TTAAACTTAAGCTTGGTACCTCACTTTA
ATGGAGAGGACGTTATG-3′, and introducing a KpnI site. This objective
gene was cloned into multiple cloning sites of pcDNA3.1 (−) (XhoI/
KpnI enzyme, Genechem, Shanghai, China) to generate the vector,
pcDNA/FX-WT.
PCR-mediated site-directed mutagenesis was performed to intro-
duce the Ala275Val mutation. Except for the conventional primers
of the 5′-end and 3′-end (mentioned above), a pair of partially
complementary oligonucleotide primers containing the mutation loci
were synthesized. The forward primer sequence, was 5′-CTAACGGC
AGTCCACTGTCTCTACCAAGCCAAG-3′, and the reverse primer sequence,
was 5′-GAGACAGTGGACTGCCGTTAGGATGTAGAACTC-3′ (underlined
letter indicates the mutated base pair). Both the wild-type and variant
cDNA vector constructs were transformed into DH5a competent cells.
DNA from the resulting colonies was used for sequence conﬁrmation.
2.6. Cell culture and transfection assays
Humanembryonic kidney (HEK293) cell culture and transient trans-
fectionwith thewild-type,mutant and vehicle plasmidwere performed
as previously described [13]. The experiment was conducted three
times independently. Supernatants of the media were collected in pre-
chilled tubes and centrifuged at 3000 g for 10 min at 4 °C to remove
cell debris, and then stored at −80 °C until analysis. Proteins were
extracted with RIPA Lysis Buffer (Beyotime, Shanghai, China), sup-
plemented with a protease inhibitor cocktail (Roche AG, Basel,
Switzerland) and PMSF (Beyotime, Shanghai, China). As described
above, FX activity of the wild-type and mutant FX was evaluated by
a one-stage clotting method based on PT or aPTT on supernatants,
and the FX antigen was detected by ELISA both in the supernatant
and cell lysate.
2.7. Quantitative real-time PCR (qRT-PCR) for FX mRNA expression
Total RNA was isolated from HEK293 cells transfected with plasmid
constructs [pcDNA3.1 (−), pcDNA/FX-WT, and pcDNA/FX-A275V]
using TRIzol reagent (TaKaRa Bio, Otsu, Japan) according to the
manufacturer's protocol. Then, 1 μg of total RNA was used to synthesize
cDNA. QRT-PCR was performed using SYBR Green qPCR Master Mix
(TaKaRa Bio, Otsu, Japan). The housekeeping gene β-actin was used as
an internal control for the cDNA quantiﬁcation in each sample, and re-
sults were derived from three independent transfection assays with
triplicate RNA samples. The primer pairs used in qRT-PCR were as
follows: FX: forward, 5′-GAAACAGACCCTGGAACGCA-3′ and reverse,
5′-GGTGAGGTTGTTGTCGCCC-3′; and β-actin: forward, 5′-TTCCAGCC
TTCCTTCCTGGG-3′ and reverse, 5′-TTGCGCTCAGGAGGAGCAAT-3′.
2.8. Expression of recombinant factor X
The recombinant protein secreted by HEK293 cells into the culture
medium was concentrated 10-fold by using an Amicon Ultra-4 10K
device (Millipore, Billerica, MA, USA). FX-WT and mutant FX-A275V
proteins from both the culturemedium and cell lysatewere electropho-
resed on 10% SDS-PAGE gel (Beyotime, Shanghai, China) under non-
reducing conditions, and transferred onto polyvinylidene diﬂuoride
membranes (Millipore, MA, USA). The polyvinylidene diﬂuoride
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antibody (Abcam, Cambridge, MA, USA) as the primary antibody and
horseradish peroxidase conjugated goat anti-mouse IgG as the second
antibody. Immunoreactions were visualized using chemiluminescence
(Millipore, MA, USA), and images were captured usingMolecular Imag-
er with Image Lab Software (Bio-Rad, CA, USA).
2.9. Subcellular localization of recombinant factor X
To determine the subcellular localization of the WT or mutant FX
protein, a ﬂuorescent antibody and two red ﬂuorescent protein
vectors that were designed to speciﬁcally label the endoplasmic reticu-
lum and Golgi apparatus, respectively, were used. HEK293 cells grown
on cover slips were transiently co-transfected with 1 μg of each plasmid
constructs [pcDNA3.1(−), pcDNA/FX-WT, or pcDNA/FX-A275V] and
1 μg of pDsRed-Monomer-Golgi vector or pDsRed2-ER vector (Clontech
Laboratories, Mountain View, CA, USA) using a PolyFect reagent. The
cells were ﬁxed in 4% paraformaldehyde for 15 min at room temper-
ature, washed three times in PBS, permeabilized in 1% Triton X-100/
PBS, and blocked using 1% BSA in PBS. Monoclonal mouse anti-
human FX antibody were incubated at 4 °C overnight, and then
ﬂuorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG
(H + L) (KPL,Gaithersburg, MD, USA) was added, followed by incuba-
tion for 1 h at room temperature. Then, the cover slips were mounted
onto glass slides with DAPI/anti-fade solution (Millipore, MA, USA),
followed by capturing ﬂuorescence images using a confocal laser scan-
ning microscope (Zeiss, LSM780, Germany).
2.10. Molecular model of the Ala275Val mutant
Molecular modeling of Ala275Val mutant was conducted by using
SWISS-MODEL [14]. The protein structure of Factor Xa (pdb: 3HPT) was
used as a homology model. Graphical representations of the structure
were prepared using PyMol (DeLano Scientiﬁc, San Francisco, CA, USA).
3. Results
3.1. FX activity and antigen assays
Blood clotting assays indicated that the patient had a dramatically
prolonged aPTT (90.2 s, reference range 25–39 s) and PT (55.4 s, refer-
ence range 8–13 s). However, all other coagulant factors involved in
the intrinsic and extrinsic coagulation pathways, including FXII, FXI,
FIX, FVIII, FVII, prothrombin, and ﬁbrinogen, were within the normal
range (data not shown). For the proband, the FX activity, based on the
PT assay, was 1.4%, and the FX antigen level was 7.3%. The FX activity
and FX antigen levels of the proband's mother were 46.2% and 23.6%,
respectively.
3.2. Gene analysis
DNA sequence analysis revealed that the proband was homozygous
in exon 7 of the F10 gene for a novel missense mutation (c.824 CNT,
p. Ala275Val), which results in an amino acid substitution that occurs
within the serine protease domain (Fig. S1). The proband's mother
was heterozygous for the same mutation. Moreover, the Ala275Val
mutation was not detected in the F10 gene of 110 unrelated healthy in-
dividuals by direct sequencing, suggesting that the Ala275Val mutation
observed in the patient is not a common polymorphism, but a novel
mutation that could possibly underlie the FX deﬁciency and other relat-
ed abnormalities.
3.3. Conservation analysis and bioinformatics prediction
Ala275 is highly conserved among different species as indicated
by multiple sequence alignment using the NCBI HomoloGene tool(Fig. S2A). And, Ala275Valmutation is predicted by two online bioinfor-
matics tools, PolyPhen2 and SIFT, to be probably damaging (Fig. S2B) or
affect protein function, respectively.
3.4. Transient expression analysis of the Ala275Val mutation
The FX:C level of the Ala275Val mutant in the conditioned media as
evaluated by one-stage clottingmethod based on PTwas 8.77%± 0.65%
(FX:C level of FX-WT was set as 100% activity), indicating a signiﬁcant
decrease in enzymatic activity in the mutant (Fig. 1A). The FX:Ag levels
of the Ala275Val variant in the conditioned medium and cell lysate
based on ELISA were 3.47%± 0.30% and 61.28% ± 11.42%, respectively,
which is suggestive of an inefﬁcient secretion or intracellular degrada-
tion of the mutant FX protein (Fig. 1B).
3.5. Mutant FX mRNA expression assay
We quantitated the mRNA expression levels of the FX-Ala275Val
mutant on transiently transfected HEK293 cells by quantitative RT-
PCR. Our results from three independent tests showed that, the mRNA
expression levels of FX-Ala275Val mutant were 1.6 ± 0.88 (mean ±
SD) of that of WT FX (mRNA expression levels in WT FX was set as
1) (Fig. 1C), indicating that the Ala275Val mutant-expressing cells did
not impact the transcription of intracellular mRNA.
3.6. Western blotting analysis of recombinant factor X
Western blotting analysis of the recombinant FX in the culture
medium and cell lysate was performed to assess the capacity of synthe-
sis and secretion in theWT and Ala275Val mutant proteins (Fig. 1D). In
the culture medium, the FX protein band (about 72 kDa) was detected
only in the WT, but not in the Ala275Val mutant. On the other hand,
these were observed in the cell lysates of both the WT and Ala275Val
mutant. However, the mutant FX protein in the culture medium could
only be detected by ELISA (Fig. 1B), and not by Western blot (Fig. 1D).
This inconsistency may be attributable to differences in the sensitivity
of various assay methods. These results indicate that the mutant
FX -Ala275Val is inefﬁciently secreted, which is consistent with
the ELISA results.
3.7. Subcellular localization of recombinant factor X protein
The subcellular localization experiments showed that the recom-
binant FX protein as represented by a green ﬂuorescent signal co-
localized with the red ﬂuorescent signal, which indicated that the endo-
plasmic reticulum expressed both WT FX protein and mutant Ala275Val
protein (Fig. 2A). Compared to theWT FX protein, the distribution of the
mutant Ala275Val protein in the Golgi apparatus was signiﬁcantly atten-
uated (Fig. 2B), which was suggestive of a transport defect of mutant FX
protein from the endoplasmic reticulum to the Golgi apparatus.
3.8. Structural analysis of the FX Ala275Val mutant
The three-dimensional structure modeling analysis of FXa was per-
formed to elucidate the effects and mechanisms underlying the FX
Ala275Val (Ala56Val in the chymotrypsinogen numbering) mutation
(Fig. 3). Homology modeling based on the Protein Data Bank (PDB)
structure of Factor Xa (3HPT) showed that the Ala56Val mutant main-
tained a similar overall structure as that of the WT. Since the Ala56Val
mutation introduced a bulky isopropyl group in place of a methyl
group right next to His57, which is one component of the catalytic
triad, it is likely that this mutation will affect the conformation of the
activation center and disrupt protein folding, which in turn leads to
transport impairment, aswell as inefﬁciency for Factor Xa to cleave pro-
thrombin. This ﬁnding was consistent with the results of our functional
studies.
Fig. 1. In vitro expression analysis of wild-type FX andmutant FX-Ala275Val transiently expressed in HEK293 cells. A: FX activity levels in the culturemediumwere evaluated by using the
one-stage PT-basedmethod. B: FX antigen levelsweremeasured by ELISA in both the culturemedium and cell lysate. The value of wild-type FXwas set as 100%, and the bars represent the
mean±SDof three repeated experiments. Compared to thewild-type FX, themutant FX antigen and activity levels in the culturemediumwere signiﬁcantly lower,whereas themutant FX
displayed only a slight reduction of FX antigen levels in the cell lysate. C: RT-PCR analysis of FX mRNA levels. Compared to the wild-type FX, the mRNA expression level of mutant FX-
Ala275Val showed a slight increase (1.6-fold), indicating that themutant FX-Ala275Val did not undergo a reduction in transcription level and instead, increased. D:Western blotting anal-
ysis of the recombinant FX protein. The FX protein was detected as a 72-kDa band. Lane1, pcDNA3.1 (−) control that was transfected with pcDNA3.1 (−) vector without the F10 gene;
Lane2, mutant FX-Ala275Val; and Lane3, wild-type FX. WT: wild-type FX; MT: mutant FX-Ala275Val; CON: negative control.
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In the present study, we diagnosed and investigated a Chinese pa-
tient with severe FX deﬁciency, who has been experiencing severe
bleeding courses since childhood. The patient exhibited signiﬁcantly
reduced FX antigen and activity levels as measured by ELISA and in
the PT-based assay, respectively. Assays on functional activity and
antigen level showed that, our case could be classiﬁed as type I FX deﬁ-
ciency. DNA sequencing of F10 gene of this patient identiﬁed a novel
homozygous mutation (c.824 CNT, p. Ala275Val). The missense muta-
tion occurred at the same nucleotide site that was previously reportedFig. 2. Subcellular localization of recombinant FX protein with the endoplasmic reticulum
pcDNA/FX-A275V, and pcDNA3.1 (−) were immunocytochemically stained with monoc
mouse IgG), endoplasmic reticulumandGolgi apparatuswere visualized by using a pDsRed2-ER
protein (red), and nucleiwere visualizedwith 4,6-diamidino-2-phenylindole (DAPI: blue). Yello
tant FX were detected in the endoplasmic reticulum; however, compared to the wild-type FX,in another Chinese patient [15], in which Ala275 was substituted by
threonine and categorized to result in type I FX deﬁciency. However,
Ala275Thr mutation occurred together with an Arg387Cys mutation as
a compound heterozygote. Based on this speciﬁc condition, themolecu-
lar pathogenesis of that patient may different from that of our present
case.
The p.Ala275 amino acid is located at the catalytic domain of the FX
protein. Interspecies analysis of amino acid residues by using the NCBI
HomoloGene tool indicated that p.Ala275 is highly conserved among
different species, which is suggestive of its vital role inmaintaining pro-
tein structure and function. This is also supported by the results of two(A) and the Golgi apparatus (B). FX in HEK293 cells transfected with pcDNA/FX-WT,
lonal mouse anti-human FX antibody (green: visualized with FITC-conjugated anti-
vector and pDsRed-Monomer-Golgi vector, respectively,which encodes a red ﬂuorescent
w ﬂuorescence in the composite images indicates co-localization. Bothwild-type andmu-
the mutant FX rarely entered the Golgi apparatus.
Fig. 3. Structural models ofwild-type andmutant Factor Xa proteins. Homologymodelingwas based on the PDB structure, 3HPT. A: FXa crystal structure. The activation center is indicated
by the red dotted line, and the catalytic triad, His57, Asp102, and Ser195, is highlighted in red sticks. B: Comparison of the structures of wild-type and mutant FXa. The alanine and valine
residues are shown in green and red spheres, respectively.
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dition, the Ala275Val (Ala56Val in the chymotrypsinogen numbering)
substitution occurs at the highly conserved 42–58 residue region
(loop-40), which is shared among all vitamin K-dependent serine pro-
teinases (Table 1). During the evolution of coagulation proteins that
was caused by gene duplication and divergence, the sequence and
structure of loop-40 was shown to be always kept back [16]. Mutations
occurringwithin this region have been shown to be responsible for type
I prothrombin, FVII, FIX, or protein C deﬁciency [17–20]. For example,
Ser354Arg mutation in prothrombin results in hypoprothrombinemia
[17], a Trp357Cys substitution in the same region of loop-40 in pro-
thrombin also causes hypoprothrombinemia [21], and a corresponding
Trp215Cys mutation in FIX leads to the phenotype of no detectable
FIX antigen in a patient with hemophilia B [22]. All of these are consis-
tent with the phenotype and genotype results found in our patient, in
which the Ala275Val mutation occurred in the highly conserved loop-
40 region that subsequently was expressed as a reduction of FX activity
and antigen level.
To reveal the mechanism of FX deﬁciency due to the p. Ala275Val
mutation, it is essential to measure the levels of FX antigen and activity
using the recombinant protein expression system. Compared to the
WT FX, the FX-Aal275Val mutant displayed a slight reduction in in-
tracellular FX levels (Fig. 1B, ELISA results and Fig. 1D, Western blot-
ting results). However, the mutant Aal275Val exhibited signiﬁcantly
lower procoagulant activity (8.77% ± 0.65%) and antigen level
(3.47% ± 0.30%) in the culture medium compared to the that of WT
FX, indicating that themutant Aal275Val retained its capacity to synthe-
size the FX protein intracellularly, but existed in secretion or efﬂux
defect. This result was also conﬁrmed by the FX mRNA expression
assay, in which the mutant FX-Aal275Val mRNA abundance slightlyTable 1
Amino acid sequence of residues 42 to 58 (chymotrypsin number-
ing) of thrombin, FXa, FIXa, FVIIa, and anticoagulant protein C.






Conserved amino acids are depicted in bold, residue Ala56 is
underlined.increased, suggesting that themutation did not inﬂuence the transcrip-
tion of the F10 gene.
Subcellular colocalization experiments showed that both WT and
mutant FXproteinswere present in the endoplasmic reticulum. Howev-
er, mutant FX was rarely detected in the Golgi apparatus compared to
WT FX, which suggests that the mutant FX-A275V that harbored a res-
idue change in its highly conserved region was unable to undergo cor-
rect protein folding and was not efﬁciently transported to the Golgi
apparatus. It is possible that themutant FX remained in the endoplasmic
reticulum andwas rapidly degraded. As has been deduced that the fold-
ing of secretory proteins takes place in the ER, the quality of the folded
proteins is carefully monitored by a group of molecules (molecular
chaperones and lectin-like proteins) that play a role in protein quality
control [23]. The ER quality control system facilitates in protein folding
[24] and allows only properly folded and assembled proteins to proceed
along the secretory pathway and be transported to its ﬁnal destination.
Misfolded or unassembled proteins are retained in the ER and subse-
quently degraded through a process known as ER-associated degrada-
tion (ERAD) [25,26]. Based on the colocalization results, we speculated
that the transportation defect of the mutant FX-A275V protein might
have arisen from the replacement of alanine (with a small side chain)
by valine (with a bulkier side chain) in the protein core, inﬂuencing
the recognition site of the intracellular folding and processing, ultimate-
ly leading to an intracellular retention in the ER and degradation.
In the FXa crystallographic structure (Fig. 3), Ala275 (Ala56 in the
chymotrypsinogen numbering), which harbors a small side chain, is lo-
cated in a tightly packed core region, just one residue before the catalyt-
ic His57. Its substitution by valine with a bulkier side chain probably
leads to the rearrangement of this tightly packed region, resulting in a
conformational change in the activation center that is formed by
amino acids His57, Asp102, and Ser195. This effect may affect protein
folding, resulting in catalytic dysfunction and secretion defect. A similar
result has been observed in the A191V mutation of the F7 gene, which
causes inherited factor VII deﬁciency [27], where A191 is also located
in the protease domain and just two residues prior to the catalytic
H193 residue. Therefore, these ﬁndings indicate that the FX Ala275Val
mutation could confer rigidity in the FX protein and impair its catalytic
activity and intracellular trafﬁcking process.
In conclusion, we report here a novel causative mutation (Ala275Val)
in the F10 gene that causes severe FX deﬁciency. Structure-function
correlation studies involving themutant FX show that Ala275 is located
in a highly conserved region that is shared by all trypsinogen-like
113N. Sun et al. / Thrombosis Research 138 (2016) 108–113proteins, and the substitution of Ala275 by Val leads to misfolding and
defective transport of the FX protein. These structural changes appar-
ently contribute to the reduction in FX coagulant activity, as well as its
defective secretion.
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